Actemra is a medicine containing the active ingredient(s) tocilizumab. On this page you will find out more about Actemra, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: tocilizumab
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Actemra 200 mg/10 mL concentrated injection, 10 mL vial
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
Rheumatoid Arthritis ACTEMRA is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients in combination with methotrexate (MTX) or other non-biological disease-modifying anti-rheumatic drugs (DMARDs) in case of either an inadequate response or intolerance to previous therapy with one or more DMARDs.,ACTEMRA is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients with poor prognostic factors (see CLINICAL TRIALS) in combination with MTX in those not previously treated with MTX.,In the two groups of patients above, ACTEMRA can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.,ACTEMRA has been shown to inhibit the progression of joint damage in adults, as measured by X-ray, when given in combination with methotrexate.,Polyarticular Juvenile Idiopathic Arthritis ACTEMRA is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response to or intolerance to methotrexate (MTX). ACTEMRA can be given alone or in combination with MTX.,Systemic Juvenile Idiopathic Arthritis ACTEMRA is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older. ACTEMRA can be given alone or in combination with methotrexate (MTX).
Table of characteristics
|Visual appearance||Clear to opalescent, colourless to pale yellow liquid|
|Dosage Form||Injection, concentrated|
|Route of administration||Intravenous Infusion|
1 vial: Prescription Only Medicine, or Prescription Animal Remedy
4 vials: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store at 2 to 8 degrees Celsius|
|Storage conditions||Do not Freeze,Protect from Light,Refrigerate|
|Life time||30 Months|
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 March 2018
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.
Found 2 results
Actemra (tocilizumab (rch)) information | myVMC
Actemra (tocilizumab (rch)) is an anti-rheumatic agent used to treat patients with active moderate to severe rheumatoid arthritis (RA).
Read more on myVMC – Virtual Medical Centre website
Xeljanz Tablets - myDr.com.au
Xeljanz Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Found 0 results